Status:
COMPLETED
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
Lead Sponsor:
Amgen
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the benefit of panitumumab in addition to best supportive care compared to best supportive care alone in patients with chemorefractory wild-type KRAS (Kirsten ...
Eligibility Criteria
Inclusion
- Diagnosis of metastatic colorectal cancer (CRC)
- Wild-type (without mutation in codons 12 and 13) KRAS gene in tumor tissue confirmed by a central laboratory
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- At least 1 measurable or non-measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines.
- Treatment failure (defined as failure due to either disease progression \[clinical or radiological\] or toxicity \[treatment intolerance\]) of a prior regimen containing irinotecan for metastatic disease and a prior regimen containing oxaliplatin for metastatic disease. Oxaliplatin and irinotecan may have been administered sequentially or in combination.
- Disease relapse within 6 months after completing adjuvant chemotherapy (with either an irinotecan or oxaliplatin containing regimen) will also be considered as treatment failure of a prior regimen for metastatic disease
- Must have previously received a thymidylate synthase inhibitor (eg, fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) at any point for treatment of CRC
- Man or woman at least 18 years of age
- Adequate hematologic, renal, hepatic and metabolic function
- Negative pregnancy test within 72 hours before randomization (for women of childbearing potential only)
- Subject or subject's legally acceptable representative has provided informed consent.
- Other protocol-specified criteria may apply
Exclusion
- Symptomatic brain metastases requiring treatment
- History of another primary cancer within 5 years of randomization
- Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (eg, panitumumab or cetuximab) or treatment with small molecule EGFR inhibitors (eg, gefitinib, erlotinib, lapatinib)
- Antitumor therapy (eg, chemotherapy, hormonal therapy, immunotherapy, antibody therapy) within 21 days before randomization
- Radiotherapy within 14 days before randomization.
- Exclusion Criteria for corrected QT (QTc) Evaluation Subpart of the Study: Prolongation of QT/QTc interval \> 450 milliseconds at screening
- Other protocol-specified criteria may apply
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2016
Estimated Enrollment :
377 Patients enrolled
Trial Details
Trial ID
NCT01412957
Start Date
November 1 2011
End Date
November 1 2016
Last Update
March 15 2017
Active Locations (78)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Curitiba, Paraná, Brazil, 80420-090
2
Research Site
Natal, Rio Grande do Norte, Brazil, 59075-740
3
Research Site
Ijuí, Rio Grande do Sul, Brazil, 98700-000
4
Research Site
Porto Alegre, Rio Grande do Sul, Brazil, 90610-000